MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
Globe Newswire•11/08/2026•16:05 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.